Edition:
United States

VentriPoint Diagnostics Ltd (VPT.V)

VPT.V on TSX Venture Exchange

0.51CAD
27 Mar 2017
Change (% chg)

$-0.03 (-5.56%)
Prev Close
$0.54
Open
$0.54
Day's High
$0.54
Day's Low
$0.50
Volume
2,325,381
Avg. Vol
1,596,101
52-wk High
$0.92
52-wk Low
$0.09

Latest Key Developments (Source: Significant Developments)

Ventripoint announces increase in size of private placement
Wednesday, 15 Mar 2017 07:00am EDT 

Ventripoint Diagnostics Ltd : Ventripoint announces increase in size of private placement, shares for debt and closing of acceptance of orders . Ventripoint Diagnostics says increasing gross proceeds of non-brokered private placement to $3.2 million, will now issue up to 10 million units at $0.32/unit .Announcing private placement is oversubscribed and no further orders will be accepted.  Full Article

Ventripoint on a joint venture in China
Friday, 23 Sep 2016 07:46am EDT 

Ventripoint Diagnostics Ltd : Ventripoint announces establishment of a joint venture in China, corporate development update, private placement and issuance of shares for debt . Has received from Yutian Technology first order for components to manufacture VMS units in China .Co expects that first VMS units will be built in the factory by end of year.  Full Article

Ventripoint Diagnostics Ltd announces strategic investment
Tuesday, 3 Nov 2015 09:30am EST 

Ventripoint Diagnostics Ltd:Intends to accept a strategic investment from Shanghai YuTian Medical Investment Management Co. Ltd by way of a private placement offering of a total of 9,090,909 units at $0.055 per Unit for total gross proceeds of up to $500,000.Corporation will use the proceeds of private placement for development, commercialization and general working capital.  Full Article

Ventripoint Diagnostics Ltd closes $3,000,000 private placement
Tuesday, 29 Sep 2015 01:29pm EDT 

Ventripoint Diagnostics Ltd:Completed previously-announced, non-brokered private placement of 54,545,454 units at $0.055 per Unit for total gross proceeds of $3,000,000.Corporation will use the proceeds of the Private Placement for development, sales and marketing and general working capital purposes.  Full Article

Ventripoint closes $800,000 private placement financing
Friday, 5 Jun 2015 08:34am EDT 

Ventripoint Diagnostics Ltd:Completes its non-brokered private placement of 14,545,450 units at $0.055 per Unit for gross proceeds of $800,000.00.Each Unit consists of one common share of Ventripoint and one half warrant.Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.  Full Article

Ventripoint Diagnostics announces increase of private placement financing
Tuesday, 2 Jun 2015 09:44am EDT 

Ventripoint Diagnostics:Says it will increase the recently announced non-brokered private placement to up to 14,545,455 units at $0.055 per Unit for total gross proceeds of up to $800,000.Each Unit will consist of one common share of Ventripoint and one half warrant.Each full Warrant will entitle the holder thereof to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.Corporation has received conditional approval of the Offering from the TSX Venture Exchange.Closing of the offering is expected to occur on or about June 4.Net proceeds of the Offering, after deducting the expenses of the Offering, will be used to incur expenditures for: (i) product and service commercialization of the VMS heart analysis system; (ii) for general working capital purposes and (iii) potentially to repay debt and outstanding payables.  Full Article

Ventripoint Diagnostics announces $700,000 private placement financing
Thursday, 28 May 2015 08:19am EDT 

Ventripoint Diagnostics:Intends to complete a non-brokered private placement of up to 12,727,272 units at $0.055 per Unit for total gross proceeds of up to $700,000.Each Unit will consist of one common share of Ventripoint and one half warrant.Each full Warrant will entitle the holder thereof to acquire one additional Common Share at a price of $0.12 per Common Share for a period of 2 years after the issuance of the Warrant.Depending on market conditions, the Corporation reserves the right to increase the maximum gross proceeds under the Offering, subject to the approval of the TSX Venture Exchange.  Full Article

VentriPoint Diagnostics Ltd Receives Marketing Clearance from the FDA to Expand the Use of the VMS Heart Analysis System
Tuesday, 26 May 2015 08:30am EDT 

VentriPoint Diagnostics Ltd:Says it has received Marketing Clearance from the U.S. Food & Drug Administration ("FDA") for the expanded Indications for Use of its VMS(TM) product which states.  Full Article

Ventripoint Diagnostics Receives Marketing Clearance From the FDA to Expand the Use of VMS Heart Analysis System
Monday, 25 May 2015 08:01am EDT 

Ventripoint Diagnostics Ltd:Receives Marketing Clearance from the U.S. Food & Drug Administration (FDA) for the expanded Indications for Use of VMS product which states; The VMS system is indicated for use where RV (right ventricle) volumes and ejection fractions are warranted or desired.  Full Article

More From Around the Web

No consensus analysis data available.